Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda announces takeover of Nycomed

Takeda announces takeover of Nycomed

20th May 2011

Takeda has announced that it will be acquiring Nycomed as part of a move to expand its presence in the European market.

A 9.6 billion euro (8.43 billion pounds) deal has been agreed that will see Nycomed become a wholly-owned Takeda subsidiary within the next 90 to 120 days, with Nycomed's US dermatology business excluded from the agreement.

Nycomed is based in Zurich and possesses both a strong European commercial network and expanding interests in emerging markets, thanks to the aggressive growth strategy it has been following since 2005.

In particular, its Daxas treatment franchise for chronic obstructive pulmonary disease has been highlighted as a potentially major source of revenue growth for Takeda in the coming years.

Yasuchika Hasegawa, president and chief executive officer of Takeda, said: "Nycomed's strength in a geographically wide range of markets and its diverse talent base will be a strong driver to helping us realise our important mission of striving toward better health for patients worldwide."

Earlier this month, the company announced a new investment in Fate Therapeutics, allowing it to gain a firmer foothold in the regenerative medicine sector.ADNFCR-8000103-ID-800550959-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.